Loading stock data…
Savara, Inc. (SVRA)
$5.53+0.16 (+2.98%)
Market ClosedLast close Sep 8
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Savara Inc. in the Healthcare sector is trading at $5.53 with a market capitalization of $1.1B. Wall Street consensus targets $10.94 (8 analysts), implying a +97.8% move over the next 12 months. The stock is currently 21% below its 52-week high of $7.00, remaining 1.1% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +97.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$38.14M↓ | -$33.42M↓ | -$30.25M↑ | -$31.44M↓ | -$27.65M |
| Net Income | -$37.28M↓ | -$32.24M↓ | -$29.56M↑ | -$30.40M↓ | -$26.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-96.97%
Volume
Today's trading volume
1.66M
Recent News
What Insmed Stock's Premium Is Actually Buying
Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.
Here's Why You Should Add Savara Stock to Your Portfolio Now
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains.
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
Recent share performance and business snapshot Savara (SVRA) has drawn attention after a period where the stock declined 3% over the past month and 9% over the past 3 months, despite a 114% total return over the past year. The clinical stage biopharmaceutical company, focused on rare respiratory diseases, has a market value of about US$1.29b and reported revenue of US$0 alongside a net loss of US$129.482m in its latest figures. See our latest analysis for Savara. At a share price of US$5.09,...
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.